View Press Releases
-
Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services
Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base
Nov 4, 2021
-
Qlucore approved for listing on Nasdaq First North Growth Market
Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.
Nov 4, 2021
-
CMOs will account for four of the five top bio manufacturing capacities in 2025
230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development
Nov 4, 2021
-
Pillar VC and Petri Announce Winners of $200K Pitch Competition
Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.
Nov 7, 2021
-
The Community Blood Center (Appleton, WI) to roll out biolog-id’s technology to support platelet lifecycle management
The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.
Nov 7, 2021
-
Birmingham Biotech and the University of Birmingham sign licensing agreement for anti-viral nasal spray against COVID-19
Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.
Nov 8, 2021
-
CHARGEPOINT TECHNOLOGY APPOINTS NEW COO TO DRIVE FUTURE GROWTH
-
Protheragen MedAI Upgrades CADD Platform to Accelerate Drug Design
-
Samsung Biologics Reports Strong Second Quarter 2021 Financial Results
-
CluePoints partners with ZS to provide best-in-class RBQM expertise and technology, increasing clinical trial efficiency and improving patient outcomes
CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight. The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight.
Aug 25, 2021
-
Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 Awards
Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.
Aug 25, 2021
-
DFE Pharma Proudly Supports COVID-19 Vaccination Supply in Pakistan
-
BOC Sciences Offers Pseudouridine and Its Derivatives for RNA Improvement
-
Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure
Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy.
Jul 29, 2021
-
Sensyne grows medical research dataset to 60 million patients
Deep longitudinal, disease agnostic structured global dataset, covering over 4,000 indications will industrialize Sensyne’s life sciences activities
Aug 1, 2021
-
Cisco fixes vulnerability that allowed criminals to remotely execute arbitrary code and control a firewall
Positive Technologies researchers discovered a vulnerability in Cisco Firepower Device Manager On-Box – a product designed to locally configure Cisco Firepower firewalls. Now patched, the flaw could allow attackers to gain full control over the device and its capabilities. That could include handing over to criminals the ability to filter traffic. Attackers could also shut down a firewall, or even access other internal resources within an enterprise, if they’re located on the same subnet.
Aug 1, 2021
-
Stelis Biopharma appoints Mark W. Womack as the new CEO
-
BIO-ISAC founded to protect and build resilience from increasing attacks on public and private bioeconomy infrastructure
-
Advanced Instruments to Acquire Solentim, a Trusted Global Leader in Cell Imaging for Cell Line Development and Clone Characterization
Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the execution of a definitive agreement to acquire Solentim, a trusted global leader of solutions for the isolation and characterization of high value single cell clones in cell line development (CLD) applications.
Aug 5, 2021
-
Amerigo Scientific Launches New AcrB Transporter for Therapeutic Indications
Amerigo Scientific recently launches AcrB transporter that aids in the identification, development, refinement, and validation of new molecules and therapeutic antibodies.
Aug 3, 2021